期刊文献+

张培彤治疗胰腺癌的临床用药规律 被引量:7

Clinical Medication Rule of Zhang Peitong in the Treatment of Pancreatic Cancer
下载PDF
导出
摘要 目的:分析张培彤治疗胰腺癌的临床用药规律并分析其学术思想。方法:收集张培彤治疗胰腺癌患者的电子处方,通过基于复杂网络分析和点式互信息方法的数据挖掘方法,分析临床常用中药、配伍药对及核心处方等用药规律。结果:147例胰腺癌患者总计就诊567次,有效中药处方567张,共计使用药物287味,使用频次共计10 476次。高频中药21味,占所有用药频次的63.5%;高频药对15组,临床常用核心处方为膈下逐瘀汤和六君二母汤。结论:张培彤临床治疗胰腺癌以扶正补虚固护中焦脾胃为主,以清热解毒、活血化瘀、消痰散结攻邪为辅,临床脾虚湿阻证为六君二母汤,气滞血瘀证为膈下逐瘀汤,其他证型辨证加减。 Objective:To analyze Zhang Peitong′s clinical medication rule in the treatment of pancreatic cancer and his academic thought.Methods:The electronic prescriptions of pancreatic cancer patients treated by Zhang Peitong were collected,and the data mining method based on complex network analysis and point mutual information method was used to analyze the rules of the clinical frequently-used herbs,compatibility of couplet medicines and the core prescription.Results:A total of 147 patients with pancreatic cancer were treated 567 times,and 567 effective prescriptions of Chinese medicine were used.A total of 287 kinds of Chinese medicine were used,and the frequency of use was 10 476 times.High-frequency Chinese medicine were 21 flavor,accounting for 63.5%of all medication frequency.High-frequency couplet medicines were 15 groups.Clinical core prescriptions were Gexia Zhuyu Decoction and Liujun Ermu Decoction.Conclusion:Zhang Peitong′s clinical treatment of pancreatic cancer is mainly to nourish the deficiency and strengthen the spleen and stomach,supplemented by clearing away heat and detoxification,activating blood circulation and removing blood stasis,eliminating phlegm and dispersing stagnation and attacking pathogens.The clinical syndrome of spleen deficiency and dampness is Liujun Ermu Decoction.Qi stagnation and blood stasis is Gexia Zhuyu Decoction.Other syndrome types are added or subtracted.
作者 吴超勇 王苗苗 张培彤 李蒙 刘槟 WU Chaoyong;WANG Miaomiao;ZHANG Peitong;LI Meng;LIU bin(Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing China 100053;Beijing University of Chinese Medicine,Beijing China 100029;The First Affiliated Hospital to Anhui Medical University,Hefei Anhui China 230022)
出处 《中医学报》 CAS 2019年第9期1889-1892,共4页 Acta Chinese Medicine
基金 国家自然科学基金项目(81673797) 北京市自然科学基金项目(7182142)
关键词 胰腺癌 数据挖掘 用药规律 张培彤 pancreatic cancer data mining medication rule Zhang Peitong
  • 相关文献

参考文献9

二级参考文献87

  • 1曹海涛,李福军,何裕民.胰腺癌的中医治疗现状[J].中医研究,2005,18(12):49-53. 被引量:4
  • 2赵玉沛,陈革.胰腺外科的新进展[J].消化外科,2006,5(2):77-80. 被引量:22
  • 3Jemal A,Siegel R,Ward E,et al. Cancer statistics[J]. CA Cancer J Clin ,2007,57 ( 1 ) :43 - 66.
  • 4HIDALGO M.Pancreatic cancer[J].N Engl J Med,2010,362(17):1605-1617.
  • 5VINCENT A,HERMAN J,SCHULICK R,et al.Pancreatic cancer[J].Lancet,2011,378(9791):607-620.
  • 6LI D,XIE K,WOLFF R,et al.Pancreatic cancer[J].Lancet,2004,363(9414):1049-1057.
  • 7BERGER A C,GARCIA M J R,HOFFMAN J P,et al.Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation:a prospective validation by RTOG 9704[J].J Clin Oncol,2008,26(36):5918-5922.
  • 8HESS V,GLIMELIUS B,GRAWE P,et al.CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial[J].Lancet Oncol,2008,9(2):132-138.
  • 9MAITHEL S K,MALONEY S,WINSTON C,et al.Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma[J].Ann Surg Oncol,2008,15(12):3512-3520.
  • 10TAKAHASHI H,OHIGASHI H,ISHIKAWA O,et al.Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival[J].Ann Surg,2010,251(3):461-469.

共引文献163

同被引文献127

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部